TScan Therapeutics announced a major corporate reorganization to fund an in vivo solid-tumor program, reducing staff by ~75% and pausing ALLOHA-2 Phase 3 enrollment. The shift concentrates capital on lead in vivo programs, with PRAME and MAGE-A4 moving into IND-enabling studies and plans for future partnerships to preserve value. Key milestones are IND in 2027 and Phase 1 development later in 2027, with data readouts anticipated through 2026–2027.
- TScan Therapeutics reported a quarterly loss of $0.32 per share, missing expectations. - Revenues for TScan were $0.57 million, significantly lower than anticipated. - TScan stock has gained 32.6% this year, outperforming the market. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
